<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974725</url>
  </required_header>
  <id_info>
    <org_study_id>CLXH254X2102</org_study_id>
    <secondary_id>2016-004293-18</secondary_id>
    <nct_id>NCT02974725</nct_id>
  </id_info>
  <brief_title>Study of LXH254 and LTT462 in NSCLC</brief_title>
  <official_title>A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize safety and tolerability and identify a recommended dose and regimen for the
      LXH254 and LTT462 combination and for the LXH254 and trametinib combination.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">November 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs) as a measure of safety and tolerability</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicities (DLTs) (dose escalation only)</measure>
    <time_frame>1 cycle (28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - (dose expansion part only)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LXH254</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LTT462</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameter (Cmax) for LXH254 &amp; LTT462:</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameter (AUC) for LXH254 &amp; LTT462</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of pharmacodynamics (PD) marker DUSP6 in tumor samples</measure>
    <time_frame>baseline, month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of trametinib</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameter (Cmax) for LXH254 &amp; trametinib</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameter (AUC) for LXH254 &amp; trametinib</measure>
    <time_frame>Up to Month 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">127</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>LXH254+LTT462</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LXH254+Trametinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>LXH254 will be supplied as tablet for oral use.</description>
    <arm_group_label>LXH254+LTT462</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTT462</intervention_name>
    <description>LTT462 will be supplied as hard gelatin capsule for oral use.</description>
    <arm_group_label>LXH254+LTT462</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Trametinib will be supplied as film-coated tablet for oral use</description>
    <arm_group_label>LXH254+Trametinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>Trametinib will be supplied as film-coated tablet for oral use</description>
    <arm_group_label>LXH254+Trametinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have advanced or metastatic NSCLC

          -  Presence of KRAS or BRAF mutation in tumor tissue

          -  All patients participating in this clinical trial must have progressed following
             standard therapy or, in the opinion of the Investigator, no effective standard therapy
             exists, is tolerated, appropriate or is considered equivalent to study treatment.

          -  ECOG (Eastern Cooperative Oncology Group) performance status â‰¤ 2

        Exclusion Criteria:

          -  Dose expansion - KRAS mutant patients groups: Prior treatment with a RAFi (including
             any BRAFi and pan-RAFi), MEKi and/or ERKi. BRAF mutant patients group: Prior treatment
             with an ERKi and/or a pan-RAFi.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days
             prior to the start study treatment and for the duration of the study.

          -  Patients with Gilbert's syndrome or other heritable diseases of bile processing.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bakhan Barzangy</last_name>
      <phone>617-726-1849</phone>
      <email>bbarzangy@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Heist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>KRAS</keyword>
  <keyword>BRAF</keyword>
  <keyword>LXH254</keyword>
  <keyword>LTT462</keyword>
  <keyword>Trametinib</keyword>
  <keyword>Non-small cell lung carcinoma (NSCLC)</keyword>
  <keyword>treatment of lung cancer after first metastasis</keyword>
  <keyword>lung cancer</keyword>
  <keyword>lung adenocarcinoma</keyword>
  <keyword>Large-cell lung carcinoma</keyword>
  <keyword>Non small cell lung carcinoma</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Large cell lung carcinoma</keyword>
  <keyword>Large cell lung cancer</keyword>
  <keyword>squamous cell lung carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

